Publications by authors named "Eduardo Barrascout"
Purpose: A retrospective monocentric comparison of progression-free survival, overall survival, clinical benefit and tolerability between elderly (age>70) and non-elderly (age ≤ 70) patients receiving bevacizumab for recurrent glioblastoma.
Methods: We analyzed 47 patients with recurrent glioblastoma receiving bevacizumab (10 mg/kg every 14 days) between January 2011 and January 2014. Bevacizumab was introduced for all patients at recurrence after a first-line treatment by temozolomide.
Article Synopsis
- - The study focused on the clinical significance of 9p allelic loss in anaplastic oligodendroglial tumors (AOTs) that have a 1p/19q codeletion and analyzed data from 216 patients.
- - Researchers found that a specific area of loss on chromosome 9 (9p21.3) occurred in 41.7% of tumors, and this was linked to poorer survival rates for patients in multiple analyses.
- - The findings suggest that 9p allelic loss could serve as a new prognostic biomarker for AOTs, highlighting the need for further research to explore this potential.
Background: Bellini carcinomas, rare tumors of kidney, are aggressive and have a poor prognosis. For these cancers, there is no standard treatment regimen and chemotherapy for urothelial cancer is usually used.
Case Report: In a 44-year-old man with hematuria, a tumor was diagnosed in the right kidney.
Receptor tyrosine kinase (RTK) inhibitors have revolutionized the treatment of metastatic renal cell carcinoma (mRCC) and significantly extended survival in these patients. Sunitinib is an oral multitargeted inhibitor of vascular endothelial growth factor receptors (VEGFRs-1, -2, and -3), platelet-derived growth factor receptors (PDGFRs-α and -β), stem-cell factor receptor (KIT), FMS-like tyrosine kinase 3 (FLT3), colony-stimulating factor 1 receptor (CSF-1R), and glial cell line-derived neurotrophic factor receptor (REarranged during Transfection; RET). Sunitinib is approved multinationally for the treatment of advanced RCC, and is considered the reference standard of care for first-line treatment.
View Article and Find Full Text PDF